Integrated Multi-Omics and Machine Learning Identify PTTG1 as a Prognostic Biomarker and Therapeutic Target in Endometrial Cancer
Source check: Source checked. Not independent scientific confirmation.
Finding: A Research Square preprint integrated TCGA and GEO multi-omics data with machine-learning feature selection to identify PTTG1 as a prognostic candidate in endometrial cancer. The authors report expression and protein-level checks in paired clinical specimens and CPTAC corroboration. This does not establish clinical utility or therapeutic efficacy.
Technology: Integrated multi-omics analysis with machine-learning prognostic modeling
Publication: Preprint · Test context: direct test. Catalog categories, not an evidence grade.
- AI contribution
- LASSO, SVM-RFE, XGBoost and Boruta were used for feature selection in TCGA/GEO transcriptomic analyses; single-cell and spatial transcriptomics informed localization of PTTG1.
- Test and result
- The preprint reports PTTG1 expression checks with Western blot, qRT-PCR and immunohistochemistry in paired clinical specimens, and CPTAC proteomic corroboration.
- Limitation / still unknown
- The reported specimen checks do not establish clinical utility or therapeutic efficacy; independent prospective validation is not reported.
Evidence sources and annotation context
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
Evidence sources: https://www.researchsquare.com/article/rs-10764988/v1 · https://europepmc.org/article/PPR/PPR1356426
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: not linked in this catalog; this does not mean no paper exists.
Review date: 22 Nov 2026. Review scope: Primary result-bearing material for the stated method, result and evaluation, with bibliographic version information..
No follow-up recorded; this is not a claim that no follow-up exists. Follow-up review scope and date are not recorded. No source-supported relationships recorded.
Editorial assessment: Impact 2/5 · Validation 3/5 · Novelty 2/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.